Laurus Labs gets EIR from USFDA for Unit 2 at Visakhapatnam

23 Jan 2020 Evaluate

Laurus Labs has received an Establishment Inspection Report (EIR) (for the Pre-Approval Inspection) from US Food and Drug Administration (USFDA) for its Unit-2 (FDF&API integrated facility) located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

The Pre-Approval Inspection (PAI) was carried out from November 04, 2019 to November 08, 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

610.90 6.70 (1.11%)
21-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.90
Dr. Reddys Lab 1199.30
Cipla 1523.30
Lupin 2115.70
Zydus Lifesciences 918.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...